We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.35 | -5.38% | 6.16 | 5.82 | 6.50 | 93,636 | 16:35:04 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.74 | 13.11M |
From May 2019 to May 2024
TIDMSNG
RNS Number : 1396K
Synairgen plc
06 April 2018
Press Release
Synairgen plc
('Synairgen' or the 'Company')
Grant of options
Southampton, UK - 6 April 2018: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that on 5 April 2018 the Board of Synairgen granted options ('Options') over 2,822,316 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 3.09 per cent. of the Company's issued share capital. The last grant of options was made in October 2015.
The Options are issued under the Company's existing Long Term Incentive Plan and are exercisable between 5 April 2021 and 4 April 2028, subject to achievement of performance criteria related to the increase in the total shareholder return of the Company. Following this grant, Synairgen has 7,281,348 options in issue, representing 7.96 per cent. of the Company's issued share capital.
Included in the number of Options granted on 5 April 2018, the following Options were issued to directors:
Hot Features
Premium
Options
Director Issued
------------- --------
Richard
Marsden 880,903
------------- --------
Dr. Phillip
Monk 636,208
------------- --------
John Ward 685,147
------------- --------
Following the issue of the Options, the interests of the directors of the Company at
5 April 2018 are as follows:
Percentage
holding
Total of fully
options Ordinary Total diluted
Director issued shares interest share capital
----------------------- ---------- ---------- ---------- ---------------
Richard Marsden 2,658,786 154,432 2,813,218 2.85%
----------------------- ---------- ---------- ---------- ---------------
Dr. Phillip Monk 1,316,592 183,439 1,500,031 1.52%
----------------------- ---------- ---------- ---------- ---------------
John Ward 1,800,464 276,506 2,076,970 2.10%
----------------------- ---------- ---------- ---------- ---------------
Simon Shaw (Note
1) - 1,474,096 1,474,096 1.49%
----------------------- ---------- ---------- ---------- ---------------
Iain Buchanan 212,765 112,741 325,506 0.33%
----------------------- ---------- ---------- ---------- ---------------
Dr. Bruce Campbell
(Note 2) - 294,259 294,259 0.30%
----------------------- ---------- ---------- ---------- ---------------
Paul Clegg (Note
3) 250,000 204,244 454,244 0.46%
----------------------- ---------- ---------- ---------- ---------------
Prof. Stephen Holgate
(Note 4) - 858,360 858,360 0.87%
----------------------- ---------- ---------- ---------- ---------------
Note 1. Simon Shaw's shareholding includes 105,516 shares held in his pension plan.
Note 2. Dr Bruce Campbell's shareholding includes 40,299 shares owned by his wife, Susan Campbell.
Note 3. Paul Clegg's shareholding includes 180,149 shares held in his pension plan.
Note 4. The holding of Professor Stephen Holgate includes 1,923 shares owned by his wife, Elizabeth Holgate.
Jody Brookes, also a person discharging managerial responsibilities, was granted 141,818 Options.
This announcement contains inside information as defined in Article 7 of the Market Abuse Regulation No. 596/2014 ('MAR')
For further information, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, James Thompson (Corporate Finance)
Stephen Norcross, Simon Johnson (Corporate Broking)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Sukaina Virji / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging scientific and clinical trial facilities at the University of Southampton and Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions. In August 2015 the Company entered into a collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis (IPF). In December 2017 the collaboration agreement was amended as Pharmaxis took on full responsibility for the programme, with Synairgen receiving a GBP5 million upfront payment and circa 17% of any future partnering proceeds from all fibrotic indications. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
-------------------------------------------------------------------------------------------------
a) Name Richard Marsden
----------------------------------------------- ------------------------------------------------
2. Reason for notification
-------------------------------------------------------------------------------------------------
a) Position / status Chief Executive Officer
----------------------------------------------- ------------------------------------------------
b) Initial notification / amendment Initial Notification
----------------------------------------------- ------------------------------------------------
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
-------------------------------------------------------------------------------------------------
a) Name Synairgen plc
----------------------------------------------- ------------------------------------------------
b) LEI 213800IMMTOPPDF8HD24
----------------------------------------------- ------------------------------------------------
4. Details of the transaction(s):
-------------------------------------------------------------------------------------------------
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
----------------------------------------------- ------------------------------------------------
b) Nature of the transaction Award of Options under the Synairgen LTIP
----------------------------------------------- ------------------------------------------------
c) Price(s) and volume(s) 880,903 Options awarded
----------------------------------------------- ------------------------------------------------
d) Aggregated information n/a
Aggregated volume Price
----------------------------------------------- ------------------------------------------------
e) Date of the transaction 5 April 2018
----------------------------------------------- ------------------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------------------------- ------------------------------------------------
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
-------------------------------------------------------------------------------------------------
a) Name Dr Phillip Monk
----------------------------------------------- ------------------------------------------------
2. Reason for notification
-------------------------------------------------------------------------------------------------
a) Position / status Chief Scientific Officer
----------------------------------------------- ------------------------------------------------
b) Initial notification / amendment Initial Notification
----------------------------------------------- ------------------------------------------------
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
-------------------------------------------------------------------------------------------------
a) Name Synairgen plc
----------------------------------------------- ------------------------------------------------
b) LEI 213800IMMTOPPDF8HD24
----------------------------------------------- ------------------------------------------------
4. Details of the transaction(s):
-------------------------------------------------------------------------------------------------
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
----------------------------------------------- ------------------------------------------------
b) Nature of the transaction Award of Options under the Synairgen LTIP
----------------------------------------------- ------------------------------------------------
c) Price(s) and volume(s) 636,208 Options awarded
----------------------------------------------- ------------------------------------------------
d) Aggregated information n/a
Aggregated volume Price
----------------------------------------------- ------------------------------------------------
e) Date of the transaction 5 April 2018
----------------------------------------------- ------------------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------------------------- ------------------------------------------------
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
-------------------------------------------------------------------------------------------------
a) Name John Ward
----------------------------------------------- ------------------------------------------------
2. Reason for notification
-------------------------------------------------------------------------------------------------
a) Position / status Finance Director
----------------------------------------------- ------------------------------------------------
b) Initial notification / amendment Initial Notification
----------------------------------------------- ------------------------------------------------
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
-------------------------------------------------------------------------------------------------
a) Name Synairgen plc
----------------------------------------------- ------------------------------------------------
b) LEI 213800IMMTOPPDF8HD24
----------------------------------------------- ------------------------------------------------
4. Details of the transaction(s):
-------------------------------------------------------------------------------------------------
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
----------------------------------------------- ------------------------------------------------
b) Nature of the transaction Award of Options under the Synairgen LTIP
----------------------------------------------- ------------------------------------------------
c) Price(s) and volume(s) 685,147 Options awarded
----------------------------------------------- ------------------------------------------------
d) Aggregated information n/a
Aggregated volume Price
----------------------------------------------- ------------------------------------------------
e) Date of the transaction 5 April 2018
----------------------------------------------- ------------------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------------------------- ------------------------------------------------
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
-------------------------------------------------------------------------------------------------
a) Name Jody Brookes
----------------------------------------------- ------------------------------------------------
2. Reason for notification
-------------------------------------------------------------------------------------------------
a) Position / status Head of Clinical Operations
----------------------------------------------- ------------------------------------------------
b) Initial notification / amendment Initial Notification
----------------------------------------------- ------------------------------------------------
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
-------------------------------------------------------------------------------------------------
a) Name Synairgen plc
----------------------------------------------- ------------------------------------------------
b) LEI 213800IMMTOPPDF8HD24
----------------------------------------------- ------------------------------------------------
4. Details of the transaction(s):
-------------------------------------------------------------------------------------------------
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
----------------------------------------------- ------------------------------------------------
b) Nature of the transaction Award of Options under the Synairgen LTIP
----------------------------------------------- ------------------------------------------------
c) Price(s) and volume(s) 141,818 Options awarded
----------------------------------------------- ------------------------------------------------
d) Aggregated information n/a
Aggregated volume Price
----------------------------------------------- ------------------------------------------------
e) Date of the transaction 5 April 2018
----------------------------------------------- ------------------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------------------------- ------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEAFLKEFEPEFF
(END) Dow Jones Newswires
April 06, 2018 07:14 ET (11:14 GMT)
1 Year Synairgen Chart |
1 Month Synairgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
